AFMD | Affimed N.V.

Healthcare | Biotechnology | Germany | NASD

Index	-	P/E	-	EPS (ttm)	-0.73	Insider Own	4.71%	Shs Outstand	149.34M	Perf Week	0.49%
Market Cap	127.46M	Forward P/E	-	EPS next Y	-0.66	Insider Trans	0.00%	Shs Float	140.95M	Perf Month	1.21%
Income	-109.00M	PEG	-	EPS next Q	-0.19	Inst Own	66.20%	Short Float / Ratio	3.84% / 7.15	Perf Quarter	-2.67%
Sales	40.70M	P/S	3.13	EPS this Y	-25.50%	Inst Trans	-3.34%	Short Interest	5.41M	Perf Half Y	-58.99%
Book/sh	0.90	P/B	0.98	EPS next Y	13.40%	ROA	-46.80%	Target Price	6.44	Perf Year	-71.96%
Cash/sh	1.15	P/C	0.76	EPS next 5Y	-	ROE	-62.20%	52W Range	0.55 - 3.40	Perf YTD	-29.22%
Dividend	-	P/FCF	-	EPS past 5Y	2.60%	ROI	-51.50%	52W High	-74.19%	Beta	2.51
Dividend %	-	Quick Ratio	5.20	Sales past 5Y	83.10%	Gross Margin	-	52W Low	59.52%	ATR	0.08
Employees	219	Current Ratio	5.20	Sales Q/Q	-43.80%	Oper. Margin	-	RSI (14)	48.51	Volatility	10.88% 9.58%
Optionable	Yes	Debt/Eq	0.13	EPS Q/Q	-58.60%	Profit Margin	-	Rel Volume	0.50	Prev Close	0.85
Shortable	Yes	LT Debt/Eq	0.08	Earnings	May 23 BMO	Payout	-	Avg Volume	756.46K	Price	0.88
Recom	1.90	SMA20	-3.69%	SMA50	5.42%	SMA200	-39.94%	Volume	380,890	Change	2.82%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-12-22	Initiated	H.C. Wainwright	Buy	$6
Oct-10-22	Downgrade	Stifel	Buy → Hold	$9 → $2
Aug-18-22	Resumed	Wells Fargo	Overweight
Mar-31-22	Initiated	Piper Sandler	Overweight	$7
Feb-23-22	Initiated	Cantor Fitzgerald	Overweight	$12
Oct-21-21	Initiated	Truist	Buy	$10
Sep-30-21	Initiated	Stifel	Buy	$12
Mar-31-21	Initiated	Credit Suisse	Outperform	$15
Mar-28-19	Initiated	SVB Leerink	Outperform
Aug-28-18	Upgrade	Jefferies	Hold → Buy
Jul-14-17	Initiated	SunTrust	Buy	$7
Aug-12-16	Downgrade	Leerink Partners	Outperform → Mkt Perform
May-19-16	Downgrade	Leerink Partners	Outperform → Mkt Perform
Dec-10-15	Initiated	Laidlaw	Buy	$15
Dec-04-15	Initiated	Wells Fargo	Outperform
Sep-09-15	Initiated	Jefferies	Hold
Aug-06-15	Reiterated	Oppenheimer	Outperform	$14 → $19
Jun-22-15	Reiterated	Jefferies	Buy	$12 → $16

Show Previous Ratings

Jun-03-23 09:00AM	Affimed Presents AFM24 Monotherapy Data in Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology and Provides Strategic Update on AFM24 Development Plan (GlobeNewswire)
May-30-23 06:30AM	Affimed to Present at the 2023 Jefferies Healthcare Conference (GlobeNewswire)
May-25-23 05:00PM	Affimed Announces Publication of AFM24 Clinical Abstracts for the Annual Meeting of the American Society of Clinical Oncology (GlobeNewswire) -10.07%
May-23-23 07:45AM	Affimed N.V. (AFMD) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -9.69%
06:37AM	Affimed N.V.: Q1 Earnings Snapshot (AP Finance)
06:30AM	Loading…
06:30AM	Affimed Reports First Quarter 2023 Financial Results and Highlights Operational Progress (GlobeNewswire)
06:15AM	Affimed Announces IND Clearance for a Phase 2 Clinical Trial Investigating AFM13 and AB-101 Combination Therapy (GlobeNewswire)
May-22-23 06:30AM	Affimed Announces Annual General Meeting of Shareholders (GlobeNewswire)
May-16-23 06:30AM	Affimed to Report First Quarter 2023 Financial Results & Corporate Update on May 23, 2023 (GlobeNewswire)
May-11-23 10:05AM	Affimed Announces Abstracts at the Annual Meeting of the European Hematology Association (GlobeNewswire)
May-05-23 06:14AM	Affimed N.V.'s (NASDAQ:AFMD) Price Is Right But Growth Is Lacking (Simply Wall St.)
Apr-26-23 10:00AM	Affimed Announces AFM24 Clinical Abstracts Accepted for the Annual Meeting of the American Society of Clinical Oncology (ASCO) (GlobeNewswire) +7.66%
Apr-17-23 04:05PM	Affimed Shares Preclinical Data on AFM13s Mechanism of Action Demonstrating Its Potential to Induce Serial Killing at the American Association for Cancer Research Annual Meeting (GlobeNewswire) +7.78%
Apr-16-23 03:00PM	Affimed Presents Final Data Demonstrating Safety and Efficacy of AFM13 Phase 2 REDIRECT Study in Patients with Heavily Pretreated Relapsed or Refractory Peripheral T Cell Lymphoma at the American Association for Cancer Research Annual Meeting 2023 (GlobeNewswire)
Apr-06-23 04:05PM	Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement (GlobeNewswire)
08:19AM	Loading…
Mar-30-23 08:19AM	Affimed N.V. (NASDAQ:AFMD) is a favorite amongst institutional investors who own 52% (Simply Wall St.)
Mar-29-23 06:30AM	Affimed Announces First Patient Successfully Dosed in the First-in-Human Study of AFM28 for the Treatment of Patients with Relapsed / Refractory CD123-Positive Acute Myeloid Leukemia (GlobeNewswire) +8.79%
Mar-27-23 06:21AM	Affimed N.V. (NASDAQ:AFMD) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-23-23 07:45AM	Affimed N.V. (AFMD) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -6.39%
06:30AM	Affimed Reports 2022 Financial Results and Operational Progress (GlobeNewswire)
Mar-16-23 06:30AM	Affimed to Report Full Year 2022 Financial Results & Corporate Update on March 23, 2023 (GlobeNewswire)
Mar-14-23 04:30PM	Affimed Announces Presentations of Clinical Data from AFM13 Phase 2 REDIRECT and Pre-clinical Data Demonstrating CD16A Shedding Facilitates Repetitive Targeting of Tumor Cells by AFM13-armed NK Cells at the Annual Meeting of the American Association for Cancer Research (GlobeNewswire)
Mar-09-23 05:00AM	AbCheck Announces Successful Completion of Research and Development Under Grant to Develop a Novel Microfluidics Technology for Functional Antibody Discovery (GlobeNewswire)
Feb-22-23 06:30AM	Affimed to Participate in Fireside Chat at the H.C. Wainwright Cell Therapy Virtual Conference (GlobeNewswire)
Feb-21-23 05:00AM	AbCheck Announces Collaboration to Apply Microfluidics Technology to the Discovery of Antibodies Against Challenging Therapeutic Neurology Target (GlobeNewswire)
Feb-08-23 06:30AM	Affimed to Present at the SVB Securities 2023 Global Biopharma Conference (GlobeNewswire) -6.78%
Jan-09-23 06:30AM	Affimed Reports on Corporate Progress and Provides Regulatory Update for AFM13 (GlobeNewswire) -10.42%
Dec-28-22 06:41AM	Investors in Affimed (NASDAQ:AFMD) have unfortunately lost 80% over the last year (Simply Wall St.)
Dec-22-22 06:30AM	Affimed Announces Approval of Clinical Trial Application in France for a Phase 1 Study of AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (GlobeNewswire)
Dec-16-22 09:35AM	Here's Why Affimed N.V. (AFMD) is Poised for a Turnaround After Losing 47.1% in 4 Weeks (Zacks)
01:01PM	Loading…
Dec-12-22 01:01PM	Analyst Says Affimed's 'Innate Cell Engagers Like No Others,' Sees Mammoth Upside (Benzinga) -33.33%
10:00AM	Affimed Presents Updated Data for AFM28 Demonstrating Efficient Elimination of Leukemic Stem and Progenitor Cells in Combination with Allogeneic NK cells in Preclinical Models of Acute Myeloid Leukemia and Myelodysplastic Syndrome at the Annual ASH 2022 Meeting (GlobeNewswire)
05:50AM	Citing Lack Of Durability, Affimed Scraps AFM13 Monotherapy Plans For NK Cell Combo (Benzinga)
Dec-10-22 03:00PM	Affimed Reports Topline Data from AFM13 Monotherapy Phase 2 REDIRECT Study in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma (GlobeNewswire)
02:20PM	Affimed Provides Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at the ASH 2022 Annual Meeting (GlobeNewswire)
Dec-01-22 04:05PM	Affimed to Host Investor Event Highlighting AFM13 Clinical Development at 2022 ASH Annual Meeting (GlobeNewswire)
Nov-17-22 04:01PM	Why Shares of Affimed Fell Thursday (Motley Fool) -14.29%
05:17AM	Affimed Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.)
Nov-15-22 07:45AM	Affimed N.V. (AFMD) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +11.27%
06:30AM	Affimed Reports Third Quarter 2022 Financial Results and Highlights Recent Clinical and Corporate Progress (GlobeNewswire)
Nov-07-22 08:05AM	Affimed Provides Data Update from Two Phase 1/2a Trials with its Innate Cell Engager AFM24 in Solid Tumor Patients at the 37th SITC Annual Meeting (GlobeNewswire) +22.56%
Nov-04-22 06:30AM	Affimed to Report Third Quarter 2022 Financial Results & Corporate Update on November 15, 2022 (GlobeNewswire) +5.41%
Nov-03-22 09:15AM	Affimed and Artiva Biotherapeutics Announce Partnership to Advance Combination Therapy of Innate Cell Engager (ICE®) AFM13 and Off-the-Shelf Allogeneic NK Cell Therapy AB-101 (GlobeNewswire) +9.47%
09:05AM	Affimed Announces Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells and Preclinical AFM28 Data at ASH 2022 Annual Meeting (GlobeNewswire)
Nov-02-22 10:01AM	Analysts Estimate Affimed N.V. (AFMD) to Report a Decline in Earnings: What to Look Out for (Zacks) -6.11%
Nov-01-22 06:30AM	Affimed to Present at the 2022 Jefferies London Healthcare Conference (GlobeNewswire)
Oct-31-22 07:20PM	7 Undervalued Biotech Stocks to Buy Before They Boom (InvestorPlace)
Oct-21-22 08:18AM	With 50% ownership, Affimed N.V. (NASDAQ:AFMD) has piqued the interest of institutional investors (Simply Wall St.) +9.21%
Oct-10-22 06:42PM	Why Affimed Stock Plummeted by Over 16% Today (Motley Fool) -16.32%
Oct-05-22 08:05AM	Affimed Announces Two Clinical Update Presentations on its Novel Bispecific Innate Cell Engager AFM24 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (GlobeNewswire) -7.41%
Sep-12-22 06:24AM	Does Affimed (NASDAQ:AFMD) Have A Healthy Balance Sheet? (Simply Wall St.)
Sep-04-22 06:05PM	Affimed To Provide a Clinical Update on AFM24 Monotherapy Dose-escalation at European Society for Medical Oncology (ESMO) Congress 2022 (GlobeNewswire)
Sep-01-22 06:30AM	Affimed to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-24-22 07:58AM	Billionaires Are Scooping Up These 3 Beaten-Down Biotech Stocks (Motley Fool)
Aug-20-22 08:48AM	Calculating The Intrinsic Value Of Affimed N.V. (NASDAQ:AFMD) (Simply Wall St.)
Aug-11-22 08:30AM	Edited Transcript of AFMD.OQ earnings conference call or presentation 11-Aug-22 12:30pm GMT (Thomson Reuters StreetEvents) -9.06%
07:45AM	Affimed N.V. (AFMD) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
06:30AM	Affimed Reports Second Quarter 2022 Financial Results and Highlights Recent Operational Progress (GlobeNewswire)
Aug-04-22 06:30AM	Affimed to Report Second Quarter 2022 Financial Results & Corporate Update on August 11, 2022 (GlobeNewswire) +10.10%
Jul-13-22 09:02AM	Affimed (NASDAQ:AFMD) shareholders have endured a 57% loss from investing in the stock a year ago (Simply Wall St.)
Jun-30-22 04:00PM	Affimed Establishes Scientific Advisory Board (GlobeNewswire)
Jun-10-22 10:31AM	Affimed Presents Preclinical Data of Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA) (GlobeNewswire) -5.11%
Jun-01-22 07:55AM	Affimed N.V. (AFMD) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
06:30AM	Affimed Reports First Quarter 2022 Financial Results and Highlights Recent Operational Progress (GlobeNewswire)
May-26-22 05:05PM	Affimed Highlights Trial Designs of Three AFM24 Ongoing Clinical Studies at the Annual Meeting of the American Society of Clinical Oncology (ASCO) (GlobeNewswire)
06:30AM	Affimed to Present at the 2022 Jefferies Healthcare Conference (GlobeNewswire)
May-25-22 03:00PM	Affimed N.V. (AFMD) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
May-24-22 06:30AM	Affimed to Report First Quarter 2022 Financial Results & Corporate Update on June 1, 2022 (GlobeNewswire)
06:30AM	Affimed Announces Annual General Meeting of Shareholders (GlobeNewswire)
May-16-22 08:00AM	Affimed Presents Data on Innate Cell Engagers AFM24 and AFM28 at 19th Meeting of the Society for Natural Immunity (GlobeNewswire)
May-14-22 08:06AM	What Percentage Of Affimed N.V. (NASDAQ:AFMD) Shares Do Insiders Own? (Simply Wall St.)
May-12-22 10:31AM	Affimed to Present Preclinical Data Demonstrating Cytotoxic Activity of its Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA) (GlobeNewswire)
May-06-22 04:02PM	Affimed Provides Update on ASCO AFM13-104 Oral Presentation (GlobeNewswire) -9.52%
Apr-27-22 05:21PM	CORRECTING and REPLACING -- Affimed N.V. (GlobeNewswire)
04:05PM	Affimed Announces Clinical Update and Trial in Progress Posters at the Annual Meeting of the American Association for Cancer Research (ASCO) (GlobeNewswire)
Apr-18-22 11:28AM	Affimed Announces Closing of Public Offering of Common Shares and Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire) -5.73%
Apr-12-22 10:02PM	Affimed Announces Pricing of Upsized $90 Million Public Offering of Common Shares (GlobeNewswire) -9.01%
04:03PM	Affimed Announces Proposed Public Offering of Common Shares (GlobeNewswire)
Apr-11-22 03:59PM	Affimed Touts Encouraging Patient Responses For Its NK Cell Therapy In Lymphoma Settings (Benzinga)
12:22PM	Why Affimed Stock Is Heating Up Today (Motley Fool)
08:09AM	SVB Leerink: Affimed's data for experimental Hodgkin's therapy is 'validating' (MarketWatch)
Apr-10-22 12:05PM	Affimed Presents Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at AACR Annual Meeting (GlobeNewswire)
Apr-08-22 04:19PM	3 Under-the-Radar Biotech Stocks That Will Zoom Higher (Motley Fool) -6.14%
01:23PM	Affimed Presents Findings from the Dose-escalation Phase of the First-in-human Study of AFM24 in Patients with EGFR-positive Solid Tumors (GlobeNewswire)
Apr-04-22 03:39PM	Is Affimed (NASDAQ:AFMD) Weighed On By Its Debt Load? (Simply Wall St.)
Mar-31-22 06:30AM	Affimed Reports 2021 Financial Results and Highlights Recent Operational Progress (GlobeNewswire)
Mar-24-22 06:30AM	Affimed to Report Full Year 2021 Financial Results & Corporate Update on March 31, 2022 (GlobeNewswire)
Mar-08-22 04:35PM	Affimed Announces Clinical Updates at the Annual Meeting of the American Association for Cancer Research (GlobeNewswire)
Feb-09-22 04:05PM	Affimed Announces Publication of Preclinical Data Demonstrating Cytotoxic Potency and Efficacy of NK Cells Precomplexed with Innate Cell Engagers after Freezing & Thawing (GlobeNewswire)
Feb-08-22 06:30AM	Affimed to Present at Upcoming Investor Events (GlobeNewswire)
Feb-04-22 09:00AM	3 Amazing Stocks That Are 60% Off Their Highs (Motley Fool)
Jan-06-22 06:30AM	Affimed Announces Completion of Enrollment in REDIRECT, the Registration-Directed Study of AFM13 in PTCL, and Provides Business Update (GlobeNewswire)
Jan-05-22 06:30AM	Affimed to Present at the 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -7.28%
Dec-13-21 09:05AM	Affimed Shares Preclinical Data on Innate Cell Engagers AFM28 and AFM13 at the 63rd American Society of Hematology Annual Meeting and Exposition (GlobeNewswire)
Dec-11-21 11:59AM	Timothy P. Lynchs Stonepine Capital Portfolio: Top 10 Healthcare Stocks (Insider Monkey)
Dec-09-21 10:38AM	Affimed (AFMD) Starts AFM24-102 Study With Roche's Tecentriq (Zacks) -8.49%
06:30AM	Affimed to Host Virtual Investor Call Today to Discuss Treatment of CD30-positive Lymphoma Patients with Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13 (GlobeNewswire)
Dec-08-21 06:30AM	Affimed Initiates Patient Recruitment for a Phase 1/2a Trial of Innate Cell Engager AFM24 in Combination with Roches Anti-PD-L1 Checkpoint Inhibitor Atezolizumab (GlobeNewswire) +5.89%
Dec-07-21 10:00AM	8 Beaten-Down Pharmaceutical Stocks That Could Skyrocket In 2022 (Motley Fool) +5.74%
Dec-05-21 06:04AM	Could The Affimed N.V. (NASDAQ:AFMD) Ownership Structure Tell Us Something Useful? (Simply Wall St.)

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia. The company also develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. In addition, it has collaboration with Artiva Biotherapeutics to develop the combination of AFM13 with Artiva's AB-101 NK cell therapy; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and research collaboration and license agreement with Genentech for the development and commercialization of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AFMD | Affimed N.V.

Upgrade your FINVIZ experience